Missouri Introduces Legislation to Add Psychedelics to “Right to Try” Statute

Residents of the state of Missouri living with terminal, life-threatening or debilitating ailments may soon be able to legally access various psychedelic drugs under a new bill, whose objective is to broaden Missouri’s current Right to Try statute.

A legislation introduced last month by Kansas City Republican Rep. Michael Davis would permit individuals who are seriously ill to use psychedelic substances such as ibogaine, MDMA, mescaline, psilocybin mushrooms, DMT and LSD, when all other approved treatment options have been exhausted and their doctor recommended it.

Davis’ HB 1176 measure calls for the Right to Try law be expanded to include the above psychedelics, which are currently classified as Schedule 1 drugs. The bill also advocates for the statewide reclassification of low-level offenses to be misdemeanors as well as the removal of felony penalties for simple possession of these psychedelic drugs.

Under the state’s current statutes, an individual found in the possession of the psychedelic drugs listed will have their charges classified under a class D felony, with the punishment being a jail term of up to seven years in prison. The Right to Try statute, which was ratified in the state of Missouri in 2014, permits people with terminal ailments to acquire investigational devices and drugs that are yet to receive approval from the FDA but doesn’t allow them to access or use Schedule 1 drugs.

Crossing Paths PAC, a political action and drug policy reform committee released a statement that quotes Davis saying that various psychedelic drugs have years of clinical research that support their safety and effectiveness profiles, yet the Food and Drug Administration has not made any move towards rescheduling these drugs. Davis added that his proposal not only aligned the state’s legislation with federal legislations with regard to investigational drug access but also protected the liberty interests of the states’ residents who believe that these psychedelic drugs could be useful in helping to treat various conditions.

Crossing Paths also observed that in 2018 State Rep. Jim Neely had introduced a bill that would have broadened the Right to Try statute to incorporate medical marijuana access without license caps. While the legislation was approved by the House, it was rejected on the Senate floor.

In addition to this, the HB 1176 legislation would also decrease criminal penalties for individuals who are not patients and are found to be in possession of the drugs listed in the measure. At the moment though, the initiative is yet to be moved to a committee and has no co-sponsors.

In related news, XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is gearing up to be a key player in the psychedelics medicines sector through an agreement intended to conduct research and development on a variety of psychedelic compounds (mescaline and LSD, for example).

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.